LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 617PMBCL.SeePrimary mediastinal
large B-cell lymphomas
(PMBCL)
PML-RARtranslocation, 444
p53 mutations and Li–Fraumeni
syndrome, 36, 47
Pneumococcal polysaccharide
vaccine, 545
Pneumocystis carinii, 124
Pneumocystis jiroveci, prophylaxis
for, 539, 545
Pneumocystis pneumonia, in
allogeneic stem cell
transplantation, 537
Pneumonitis, 88, 93–94, 535
Poly (ADP-ribose) polymerase
(PARP), 126, 131–132
Polycyclic aromatic hydrocarbons
and lung cancer, 33, 43
Polymerase chain reaction (PCR),
437, 443, 498
role of, 3, 10
Polymyositis, 217, 223
Polyomaviruses, in human cancers,
40, 53
Pomalidomide, 471
Pontine damage, signs of, 504,
507
Positive predictive value (PPV),
142, 145–146
Positron emission tomography
(PET), 165, 176, 216, 223,
416
of cervical cancer, 317, 325
thyroid carcinoma and, 350, 358
Posteroanterior (PA), 216, 223
Postmenopausal breast cancer and
obesity, 62, 68
Posttransplant disease relapse risk,
526, 532
Posttransplant lymphoproliferative
disorder (PTLD), 543, 549
Power and hypothesis testing, in
clinical trial, 186, 193
PPV.SeePositive predictive value
(PPV)
PR.SeePartial response (PR)
Pralatrexate, 124, 129
PRAME expression, in melanoma,
108, 113
Predictive factor, 336, 344
Prednisone, 442
in radiation pneumonitis, 558
Preoperative chemotherapy, 369,
371, 373
Preprocedural imaging, importance
of, 171
Prevalence, calculation of, 69, 74
Primary angiogenic factor, 21, 29Primary biliary cirrhosis and
cholangiocarcinoma risk, 253,
257
Primary caregiver burnout, factors
for, 563, 568
Primary CNS lymphoma (PCNSL),
421, 433, 498, 501
EBV and, 384, 389
management and therapy of, 421,
433
optic nerve involvement, 421, 433
primary leptomeningeal
lymphoma, 421, 433
Primary induction chemotherapy, in
germ cell cancer, 95, 100
Primary mediastinal large B-cell
lymphomas (PMBCL), 419,
432
Primary peritoneal carcinoma, 490,
494
surgical debulking and
intraperitoneal
chemotherapy in, 491, 495
Primary prevention, defined, 141,
145
Process measure, 583, 586
Prognostic factor, 336, 344
Programmed cell death pathway,
98, 102
Prolonged azoospermia, antitumor
agents and, 555, 559
Prometaphase, 17, 25
Prophase, 17, 25
Prophylactic cranial irradiation
(PCI), 206, 211
Prophylactic gastrectomy, 157
in gastric cancer, 237, 243
Prophylactic oophorectomy, 480
Prophylactic surgery
cryptorchidism and, 80, 83
multiple endocrine neoplasia type
2 and, 80, 83
ulcerative colitis and, 80, 83
Prostate cancer
African-American men and, 144,
147
bone pain from, 564, 569
castrate-resistant, 287, 295
dietary or lifestyle component in,
286, 294
docetaxel-based chemotherapy
for, 286, 294
Gleason score and, 284, 292
GSTloss and, 286, 294
interstitial radiotherapy and, 284,
292
and metastases to brain, 510, 513
MRI of, 169, 181–182
NKX3.1 and, 286, 294and osteoblastic lesions, 23, 31
radical retropubic prostatectomy
and, 284, 292
risk factors for, 286, 294
screening, serum PSA in, 181
three-dimensional conformal
radiotherapy and, 284, 292
TMPRSS2 and, 281, 286, 290,
294
vitamin E and, 283, 291
Prostate Cancer Prevention Trial,
291
Prostate intraepithelial neoplasia
(PIN), 286, 294
Prostate-specific antigen (PSA),
106, 110, 142, 165, 176
Protease inhibitors, 500
Proteasome, inhibition of, 96, 101
Protein
colocalization of, 16
synthesis, 25
Protein kinase A, 7, 16
Proteome, defined, 3, 10
Proteomics
technologies, limitations of, 10
usage of, 3, 10
Protooncogene, 2, 9, 22
Protooncogenes encode genes, 18,
26
PS.SeePerformance status (PS)
PSA.SeeProstate-specific antigen
(PSA)
Pseudomyxoma peritonei,
prognostic factor in, 488, 492
Psychotherapy, in cancer patients,
566, 571
PTCL.SeePeripheral T cell
lymphomas (PTCL)
PTENgene and cancer
susceptibility, 36, 47–48
PTEN mutation
in endometrial cancer, 315, 323
in ovarian cancer, 307, 312
p53 tumor suppressor gene and
gastric cancer, 233, 239
Pulmonary embolism, treatment of,
173–174
Puma, 19, 27
Pure choriocarcinoma, 297, 301
Pure red cell aplasia, 217, 223, 224
Pyoderma gangrenosum, pancreatic
cancer and, 519, 52317q21,BRCA1gene in, 332, 341
5q-syndrome, 461
Quality data sources, 587
Quality improvement, strategies for,
583, 587
Quality measurement, 586–587